ZL-1503

N/A

Report date: 2026/05/28 20:00:21

Base Information

Drug NameZL-1503
Drug Alias NameZL-1503
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-IL13Interleukin-31 inhibitors
TargetsInterleukin-13Interleukin-31
Therapy Area/IndicationsDermatitis, Atopic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNew ZealandMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZai Lab Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesZai Lab LtdZai Lab (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsDermatitis, Atopic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A